Authors: Steve Morgan, Kenneth L Bassett, James M Wright, Lixiang Yan
DOI: 10.1371/journal.pmed.0020080
Abstract Summary
Despite evidence supporting thiazide diuretics as cost-effective first-line hypertension treatment, only 9-38% of seniors received them initially. Analysis of 82,824 British Columbia patients (1993-2000) showed prescribing rates varied by comorbidities, with women and older patients more likely to receive thiazides. The gap between clinical evidence and practice suggests significant health and economic costs.
Why Brain? ðŸ§
Despite evidence supporting thiazides as first-line hypertension treatment, only 9-38% of seniors received them initially. Prescribing practices don’t align with clinical trial evidence, impacting health outcomes and costs.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
